Akti-1/2 (Akti1/2 from Selleck) Inhibits AKT Kinase in Propionate Metabolic High-Risk Ovarian Cancer
Copy code to add this image to your page
Ovarian cancer (OC) exhibits extensive metabolic heterogeneity that frequently confers resistance to standard chemotherapeutic regimens. Dysregulation of short-chain fatty acid pathways, particularly propionate metabolism, alters intracellular redox states and epigenetic remodeling through acetyl-CoA and succinyl-CoA intermediates. Transcriptomic profiling of primary ovarian carcinoma tissues identified five propionate metabolism-related genes (PMRGs)—specifically ALDH5A1, CETP, GRIA1, PTH, and TPMT—that reliably stratify patients into distinct prognostic risk tiers. Elevated risk scores in this model strongly correlate with decreased overall survival, distinct immune cell infiltration patterns, diminished tumor purity, and increased immune evasion capabilities.
To translate these metabolic signatures into actionable therapeutic strategies, quantitative drug sensitivity screening was conducted across risk-stratified patient cohorts utilizing established pharmacological target identification strategies. Among evaluated small-molecule libraries, the allosteric AKT inhibitor Akti-1/2 demonstrated marked differences in half-maximal inhibitory concentration (IC50) between high-risk and low-risk groups. Biological characterization revealed that high-risk tumors, characterized by suppressed ALDH5A1 expression and perturbed propionate flux, display elevated baseline phosphorylation of AKT at residues Thr308 and Ser473. Application of Akti1/2 from Selleck effectively abrogated this compensatory hyperactivation under tested in vitro assay conditions.
The molecular mechanism underlying this differential sensitivity involves a mechanistic crosstalk between propionate metabolic intermediates and the PI3K/AKT/mTOR signaling axis. Reduced ALDH5A1 catalytic activity causes an accumulation of succinic semialdehyde and altered mitochondrial oxidative phosphorylation, triggering compensatory activation of survival cascades mediated by AKT Kinase B. By binding to the pleckstrin homology (PH) domain of unphosphorylated AKT1 and AKT2 isoforms, Akti-1/2 locks the enzyme in an inactive, closed conformation. This structural locking prevents recruitment to the plasma membrane, blocking upstream phosphorylation by PDK1 and mTORC2. Consequently, downstream effector signaling through GSK3beta and mTORC1 is suppressed, selectively impairing cell viability in propionate metabolism-disrupted phenotypes.
Pharmacological Profiling and Metabolic Risk Stratification
Copy code to add this image to your page
Akti-1/2 is a selective, allosteric inhibitor of AKT1 and AKT2 isoforms. By binding to the pleckstrin homology (PH) domain, Akti-1/2 prevents membrane translocation and subsequent phosphorylation at Thr308 and Ser473. In ovarian cancer models characterized by high propionate metabolism prognostic risk scores, elevated baseline AKT activation renders tumor cells particularly vulnerable to this allosteric suppression, leading to inhibition of downstream mTORC1 signaling, restored apoptotic signaling, and attenuation of immune escape features.
Differential IC50 Response Correlates with PMRG Risk Scores
Drug sensitivity assays across primary ovarian cancer cultures revealed a strong inverse relationship between PMRG prognostic risk scores and Akti-1/2 IC50 values. High-risk cell lines demonstrated heightened sensitivity to allosteric AKT inhibition. Calculated IC50 values dropped significantly in ALDH5A1-depleted models; control models retained baseline resistance. This selective vulnerability aligns with elevated baseline AKT phosphorylation observed in high-risk tumors. Application of Akti1/2 from Selleck effectively suppressed downstream phosphorylation of GSK3beta and S6 Kinase within two hours of administration under tested in vitro assay conditions. The selectivity margin remained intact across varying glucose concentrations.
Immune Microenvironment Contexture Influences Kinase Inhibitor Sensitivity
High-risk ovarian cancer microenvironments display reduced tumor purity alongside elevated infiltration of immunosuppressive M2-polarized macrophages. Cellular interactions within these low-purity matrices promote paracrine cytokine secretion. Paracrine signaling sustained intrinsic survival signals; Akti-1/2 suppressed this microenvironment-mediated resistance cascade. In patient-derived cell models, treatment with Akti1/2 from Selleck reduced expression of immune escape markers, including PD-L1, in a concentration-dependent manner. Cell viability decreased sharply following target engagement. Preliminary data suggest that combining allosteric AKT inhibitors with metabolic modulators reduces macrophage-mediated protection of tumor cells.
Metabolic Flux Divergence Regulates Sensitivity to Akti-1/2
Disruption of propionate degradation pathways alters intracellular pool levels of succinyl-CoA and methylmalonyl-CoA. Altered short-chain fatty acid metabolism directly drives compensatory kinase reliance. Enzymatic inhibition attenuated downstream mTOR cascades within four hours of treatment. Intracellular metabolite pools shifted consistently during drug exposure. Within this specific cellular context, Akti-1/2 selectively induced apoptotic cascades in cells exhibiting low ALDH5A1 activity while sparing metabolically normal control lines. Target residence time correlated with sustained inhibition of glucose uptake.